Nyxoah S.A. (NASDAQ:NYXH – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $20.60.
NYXH has been the topic of several research analyst reports. Cantor Fitzgerald lifted their target price on Nyxoah from $10.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, February 9th. Stifel Nicolaus upped their price objective on shares of Nyxoah from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price (up previously from $18.00) on shares of Nyxoah in a research report on Wednesday, March 20th. Oppenheimer boosted their price target on shares of Nyxoah from $17.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, March 14th. Finally, Piper Sandler increased their price objective on Nyxoah from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th.
Get Our Latest Stock Analysis on NYXH
Nyxoah Stock Performance
Nyxoah (NASDAQ:NYXH – Get Free Report) last released its earnings results on Tuesday, March 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.41). Nyxoah had a negative return on equity of 38.58% and a negative net margin of 993.28%. The company had revenue of $1.96 million during the quarter, compared to analyst estimates of $2.01 million. Research analysts forecast that Nyxoah will post -1.78 EPS for the current fiscal year.
Institutional Investors Weigh In On Nyxoah
Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. acquired a new position in Nyxoah during the first quarter worth $8,177,000. Sei Investments Co. acquired a new position in shares of Nyxoah during the 2nd quarter valued at about $265,000. Millennium Management LLC bought a new position in shares of Nyxoah in the 4th quarter valued at approximately $51,000. ExodusPoint Capital Management LP acquired a new stake in Nyxoah in the 1st quarter worth approximately $97,000. Finally, AXA S.A. lifted its holdings in Nyxoah by 1.4% in the 1st quarter. AXA S.A. now owns 217,000 shares of the company’s stock worth $1,621,000 after purchasing an additional 3,000 shares during the last quarter.
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Featured Stories
- Five stocks we like better than Nyxoah
- Do ETFs Pay Dividends? What You Need to Know
- Comprehensive PepsiCo Stock Analysis
- 5 discounted opportunities for dividend growth investors
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Consumer Discretionary Stocks Explained
- Bear Market Funds to Watch This Year
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.